Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress defined--short-term efficacy, long-term effectiveness.

J Kane1

  • 1Department of Psychiatry, Long Island Jewish Medical Center, New York, USA. psychiatry@lij.edu

International Clinical Psychopharmacology
|March 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction of an assessment toolkit associated with increased rate of DLB diagnosis.

Alzheimer's research & therapy·2021
Same author

No role for tri-iodothyronine (T3) testing in the assessment of levothyroxine (T4) over-replacement in hypothyroid patients.

British journal of biomedical science·2016
Same author

Clinician referrals for stress echocardiography: are we compliant with the NICE guidelines?

Echo research and practice·2015
Same author

A long-term study of labetalol in general practice.

British journal of clinical pharmacology·2015
Same author

Creutzfeldt-Jakob disease and ENT.

The Journal of laryngology and otology·2013
Same author

Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.

Annals of surgical oncology·2013
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

New atypical antipsychotics offer improved schizophrenia management by addressing all symptom domains and enhancing patient outcomes. These drugs demonstrate efficacy in clinical trials for comprehensive symptom relief and relapse prevention.

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Neuroscience

Background:

  • Schizophrenia management remains challenging despite advances in therapy.
  • Treatment goals have evolved towards comprehensive symptom relief and improved functional outcomes.

Purpose of the Study:

  • To evaluate the role of atypical antipsychotics in modern schizophrenia management.
  • To assess the efficacy and tolerability of atypical antipsychotics in addressing diverse symptom domains.

Main Methods:

  • Review of evidence from randomized, double-blind trials.
  • Analysis of atypical antipsychotics' impact on positive, negative, affective, and cognitive symptoms.

Main Results:

  • Atypical antipsychotics show high efficacy across all symptom domains of schizophrenia.

Related Experiment Videos

  • These agents offer improved tolerability, notably a low risk of extrapyramidal symptoms.
  • Evidence supports their effectiveness in preventing relapse during long-term use.

    • Conclusions:

    • Atypical antipsychotics represent a significant advancement in schizophrenia treatment.
    • They provide a valuable option for the first-line management of schizophrenia.
    • These medications contribute to improved global psychopathology and functional outcomes.